20th Apr 2022 09:16
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Receives preliminary approval from the US Federal Trade Commission for its planned acquisition of Custopharm Inc. Back in September, Hikma agreed to buy the California, US-based generic injectable products company for a total of up to USD425 million.
Current stock price: 2,068.00 pence, down 0.6% on Wednesday
12-month change: down 13%
By Tom Budszus; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Hikma Pharmaceuticals